Overview
Scope and Methodology
Market Context
Exhibit 1: Distribution of Molecular Diagnostics Testing in U.S. 2004
Infectious Disease Testing: Targets and Trends
Chlamydia trachomatis
Neisseria gonorrhoeae
Pneumonia
Human Immunodeficiency Virus (HIV)
Tuberculosis
Hepatitis B Virus (HBV)
Hepatitis C Virus (HCV)
Herpes Simplex Virus (HSV)
West Nile Virus (WNV)
Products and Progress of Note
Exhibit 2: Commercially Available Molecular Diagnostic Tests for Infectious Diseases...........
Recent Research Studies: Prospects and Advances in Testing
Number of Tests
Exhibit 3: Projected Infectious Disease Testing by
Molecular Diagnostics in U.S. 2003-2013
Exhibit 4: Trending in Projected Test Volume for
Molecular Diagnostics in Infectious Disease Testing in U.S. 2003-2013
Exhibit 5: Trending in Projected Test Volume Composition for
Molecular Diagnostics in Infectious Disease Testing in U.S. 2003-2013
Market and Cost per Test Projections, 2003-2013
Exhibit 6: Projected Molecular Diagnostics Infectious Disease Testing
Market Potential in U.S. 2003-2013
Exhibit 7: Trending in Projected Market Potential for
Molecular Diagnostics in Infectious Disease Testing in U.S. 2003-2013
Exhibit 8: Trending in Projected Market Potential Composition for
Molecular Diagnostics in Infectious Disease Testing in U.S. 2003-2013
Exhibit 9: Trending in Projected Estimated Cost Per Test (ECPT) for
Molecular Diagnostics in Infectious Disease Testing in U.S. 2003-2013
Major Competitors
Abbott Diagnostics (Division of Abbott Laboratories)
Affymetrix, Inc.
Ambion RNA Diagnostics (Division of Ambion, Inc.)
Celera Genomics/Celera Diagnostics (Division of Applera Corporation)
Cenetron Diagnostics
Cepheid, Inc.
Chiron Corporation
Dharmacon, Inc.
Digene Corporation
Gen-Probe Incorporated
Innogenetics NV
Nanogen, Inc.
Roche Diagnostics Division/
Roche Molecular Systems F. Hoffmann-LaRoche Ltd.